A review of the potential mechanisms for the lowering of colorectal oncogenesis by butyrate

Kim Y. C. Fung1,2*, Leah Cosgrove1,2, Trevor Lockett1,3, Richard Head1 and David L. Topping1,2,3,4

1CSIRO Preventative Health National Research Flagship, Adelaide, SA 5000, Australia
2CSIRO Food and Nutritional Sciences, Adelaide, SA 5000, Australia
3CSIRO Food and Nutritional Sciences, North Ryde, NSW 2113, Australia
4CSIRO Food Futures National Research Flagship, North Ryde, NSW 2113, Australia

(Submitted 26 September 2011 – Final revision received 13 April 2012 – Accepted 16 April 2012 – First published online 7 June 2012)

Abstract
Colorectal cancer (CRC) is a leading cause of preventable cancer deaths worldwide, with dietary factors being recognised as key risk modifiers. Foods containing dietary fibre are protective to a degree that the World Cancer Research Fund classifies the evidence supporting their consumption as ‘convincing’. The mechanisms by which fibre components protect against CRC remain poorly understood, especially their interactions with the gut microbiome. Fibre is a composite of indigestible plant polysaccharides and it is emerging that fermentable fibres, including resistant starch (RS), are particularly important. RS fermentation induces SCFA production, in particular, relatively high butyrate levels, and in vitro studies have shown that this acid has strong anti-tumorigenic properties. Butyrate inhibits proliferation and induces apoptosis of CRC cell lines at physiological concentrations. These effects are attributed to butyrate’s ability to alter gene transcription by inhibiting histone deacetylase activity. However, the more recent discovery of G-protein coupled receptors that bind butyrate and other SCFA and data obtained from proteomic and genomic experiments suggest that alternative pathways are involved. Here, we review the mechanisms involved in butyrate-induced apoptosis in CRC cells and, additionally, the potential role this SCFA may play in mediating key processes in tumorigenesis including genomic instability, inflammation and cell energy metabolism. This discussion may help to inform the development of strategies to lower CRC risk at the individual and population levels.

Key words: Resistant starch: Butyrate: Colorectal cancer: SCFA: Fibre

Colorectal cancer (CRC) has emerged as one of the most prevalent types of cancer worldwide and is the fourth most common cause of cancer mortality (1). CRC incidence varies considerably across geographical regions. It is the highest (approximately 20–45 per 100 000) among affluent societies such as Australia/New Zealand, Europe, the USA and the UK, and the lowest among African and Asian countries (approximately 5–20 per 100 000)(1). Japan currently records the highest incidence of CRC and this appears likely to persist and continue over time(2,3). In countries such as Korea, Singapore and Eastern Europe, the incidence of disease is approaching that of high-risk countries with a longer history of affluence(2,4,5). This increase in the risk of CRC has been attributed to industrialisation and accompanying environmental influences associated with a transition from a low- to high-income economy(2). Epidemiological studies have drawn strong correlations between CRC incidence and modifiable lifestyle factors such as body weight, diet, physical activity, smoking and alcohol consumption(4,5). These associations indicate the strong possibility of CRC prevention and it is believed that 30–60% of cases can be prevented with appropriate nutrition and diet(6,7).

Dietary fibre is one of the most promising candidates for a protective role in CRC, with strong support from epidemiological and experimental animal studies. However, there is a degree of ambiguity in the population data, with some studies showing no significant effect(8,9). This may reflect the food sources of fibre. Recently, the European Prospective

Abbreviations: APC, adenomatous polyposis coli; CRC, colorectal cancer; GADD, growth arrest and DNA damage-inducible; GPR, G-protein coupled receptors; HDAC, histone deacetylase; HIF, hypoxia inducible factor; MAPK, mitogen-activated protein kinase; MCT1, monocarboxylate transporter 1; miRNA, micro-RNA; RS, resistant starch.

* Corresponding author: Dr K. Y. C. Fung, fax +61 8 8303 8899, email kim.fung@csiro.au
Investigation into Cancer and Nutrition reported that although total dietary fibre was associated with a 30% reduction in CRC risk, no one food source offered more protection than another(8). While fibre is derived largely from plant foods, it must be recognised that any protective effects of particular fibre-containing food subgroups (e.g. fruits and vegetables) can also be contributed by other nutrients present such as β-carotene, lycopene and polyphenols(10). Dietary fibre consists largely of plant polysaccharides that resist human small-intestinal enzymes and some of the protection against colorectal tumorigenesis may reflect this bulking action. Greater stool mass is expected to lower the exposure of colonocytes to carcinogens and mutagens through physical dilution and also through reduction in transit time. There is also a strong case for protection through the interactions between the large-bowel microbiome and fibre polysaccharides, which are emerging as a critical factor in the promotion of optimal colonic function(11,12). As in obligate herbivores, so too in humans, there is substantial microbial fermentation of fibre with SCFA, primarily acetate, propionate and butyrate, as significant end products(12,13). The rate of fermentation of fibre varies according to type and food source; e.g. fibre derived from grains is fermented much more slowly and less completely than that from fruits and vegetables(14,15). Cellulose is a major constituent of plant cell walls in both cereals and fruits and vegetables, but there are major differences between the two groups. Soluble fibre polysaccharides are generally higher in fruits and vegetables, reflecting their higher content of uronic acids. In contrast, cereal grains contain more arabinoxylans, mixed-linkage glucans and oligosaccharides(16,17). There is also a major difference between the various fibre polysaccharides (e.g. NSP and resistant starch (RS)) in the profile of SCFA which are produced. In the diets of industrialised countries at high risk of CRC (e.g. Australia), fibre intake is largely as cereal NSP with relatively little RS. In contrast, it appears that in traditional agrarian societies at low risk, NSP intakes are comparatively low but RS intakes are high. This is likely to be a significant factor in disease as RS fermentation favours butyrate production over that of NSP and large-bowel butyrate levels are higher when foods common to such populations are consumed(18). Importantly, butyrate is the primary energy source for colonocytes where its oxidation contributes to at least 60% of the cell’s energy requirements(19) and it is the SCFA most associated with protection against colorectal carcinogenesis(20).

This review focuses on how butyrate, a SCFA produced in the colon by the fermentation of dietary fibre, potentially prevents colorectal oncogenesis. Here, we review the experimental data derived from in vitro and animal model systems describing the mechanisms, in addition to histone deacetylase (HDAC) inhibition, influencing butyrate’s anti-tumorigenic actions. Taken together, these data provide compelling evidence to support human intervention studies to determine the true potential of RS in lowering the risk of colorectal oncogenesis in the wider population.

Anti-tumorigenic properties of butyrate
SCFA play a significant role in maintaining the normal physiological functions of the colonic mucosa(12) (Fig. 1). Although acetate is the most abundant colonic SCFA, butyrate has been studied the most due to its potent anti-tumorigenic properties. Butyrate inhibits proliferation and induces differentiation and apoptosis of CRC cells in vitro at concentrations similar to those found in the large bowel in vivo. Increased butyrate supply reduces the incidence of carcinogen-induced colon tumours in rodent models, partly through induction of apoptosis(21,22). It also opposes diet-induced colonocyte

![Fig. 1. The effects of butyrate in the normal colon and in colorectal tumour cells. HDAC, histone deacetylase.](https://www.cambridge.org/core)
DNA damage in animals, supporting its potential to promote genetic stability\(^{(23)}\). Animal experiments have shown that consumption of red meat induces the formation of N-nitroso-compounds and DNA adducts, in particular the O\(^{6}\)-methyl-adduct of \(\Lambda\)-deoxyguanosine\(^{(24)}\). Moreover, it has been shown that tissues display different abilities in the removal of these adducts\(^{(25)}\). Failure to remove these adducts via either intrinsic DNA repair mechanisms or apoptosis results in the elevation of mutation rates. Where mutations occur in key oncogenes (e.g. Kirsten rat sarcoma viral oncogene homolog; \(KRAS\)) or tumour suppressor genes (e.g. \(p53\)), the risk for CRC development can rise dramatically\(^{(26,27)}\).

The effects of butyrate are highly selective for cancer cells and its ability to modulate numerous cellular processes has contributed to the difficulty in identifying the precise mechanisms underlying each of its anti-tumorigenic properties, in particular the ability to induce apoptosis. Some of the key molecules mediating butyrate's action are summarised in Table 1. Many proteomic and transcriptomic studies have been conducted to understand the signalling pathways involved in butyrate-induced apoptosis\(^{(28–33)}\) and also to understand the mechanisms involved in the development of butyrate resistance; i.e. how a sub-population of cancer cells circumvents apoptosis in a butyrate-rich environment to become butyrate-resistant cells; i.e. how a sub-population of cancer cells circumvents apoptosis in a butyrate-rich environment to become butyrate-resistant cells. These pathways appear to be activated in parallel to amplify the apoptotic response to butyrate with induction of GADD153 in HCT116 cells. In the RKO CRC cell line, butyrate activated the c-Jun N-terminal kinase (JNK) but not the p38 arm of the MAPK signalling pathway and this correlated with caspase activation and apoptosis\(^{(46)}\). Tong et al.\(^{(45)}\) reported the loss of expression in both mouse and human intestinal tumours, lending further support to its role in intestinal tumour formation. Butyrate is also reported to increase phosphorylation of p38 and its downstream target heat shock protein 27 in both HCT116 CRC cells and MCF7 breast cancer cells\(^{(29,47)}\). Although the apoptotic response to butyrate is dependent on the cell line being studied, in each case, the activation of MAPK signalling occurs within minutes of butyrate exposure. This indicates that induction of a cell stress response occurs as an early event in butyrate-induced apoptosis.

### Effect of butyrate on processes involved in tumorigenesis

#### Genomic instability and epigenetic regulation

**Histone deacetylase inhibition.** Regulation of gene expression via inhibition of HDAC activity is the primary mechanism associated with butyrate-induced apoptosis. HDAC inhibitors (including butyrate) target the transcription of less than 10% of the human genome selectively and their cellular effects are also mediated by modulating the acetylation state of both histone and non-histone proteins including transcription factors, structural proteins and proteins involved in signal transduction\(^{(48)}\). Our knowledge of the number of non-histone proteins modified as a result of butyrate treatment is limited but is known to include the Sp1 and Sp3 transcription factors\(^{(49,50)}\). Although the functional consequences of Sp1 and Sp3 acetylation by butyrate are not known, acetylation of Sp1 has been hypothesised to increase p21 expression and mediate p53-dependent cell cycle arrest in CRC cell lines\(^{(49)}\). Identification of other non-histone protein targets acetylated by butyrate treatment may provide new insights into butyrate’s mechanisms of action.

**Role of p53 in cell cycle arrest and apoptosis.** *In vitro* studies have shown consistently that butyrate induces cell cycle arrest and apoptosis in both a p53-dependent and -independent manner at physiologically relevant concentrations (0.6–5 mmol/l)\(^{(51)}\). In CRC cell lines, butyrate downregulates the expression of p53 mRNA and protein and also directly increases the expression of p53 target genes (e.g. p21\(^{(52,53)}\), p27 and cyclin-dependent kinases) to induce cell cycle arrest\(^{(52,53)}\). Activation of p53 and its translocation to the nucleus is regulated by post-translational modifications, including acetylation by histone acetyltransferases such as p300, that can increase both the stability and pro-apoptotic activity of p53\(^{(54)}\). Prolonged or transient hyper-acetylation of p53 by HDAC inhibitors such as butyrate may represent an additional mechanism making an impact on p53-dependent apoptosis\(^{(55)}\).

**Butyrate and micro-RNA regulation.** Butyrate also alters gene expression independently of HDAC inhibition by regulating the expression of micro-RNA (miRNA)\(^{(56,57)}\).
<table>
<thead>
<tr>
<th>Gene ID</th>
<th>Gene/protein name</th>
<th>Biological role</th>
<th>Effect of butyrate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apoptosis, cell cycle, stress response</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDAC</td>
<td>Histone deacetylase</td>
<td>Family of proteins that regulate gene transcription</td>
<td>Butyrate inhibits HDAC activity</td>
</tr>
<tr>
<td>CDKN1A</td>
<td>Cyclin-dependent kinase inhibitor 1A, p21</td>
<td>Cell cycle regulator</td>
<td>Expression is induced by butyrate to cause cell cycle arrest</td>
</tr>
<tr>
<td>CDKN1B</td>
<td>Cyclin-dependent kinase inhibitor 1B, p27</td>
<td>Cell cycle regulator</td>
<td>Expression is induced by butyrate to cause cell cycle arrest</td>
</tr>
<tr>
<td>CDK</td>
<td>Cyclin-dependent kinases</td>
<td>Cell cycle regulator</td>
<td>Expression is induced by butyrate to cause cell cycle arrest</td>
</tr>
<tr>
<td>CCND1</td>
<td>Cyclin D1</td>
<td>Cell cycle regulator</td>
<td>Butyrate reduces expression</td>
</tr>
<tr>
<td>GADD</td>
<td>Growth arrest and DNA-inducible gene family</td>
<td></td>
<td>Expression is induced by butyrate to cause cell cycle arrest</td>
</tr>
<tr>
<td>MAPK</td>
<td>Mitogen-activated protein kinase family, includes p38, JNK, ERK</td>
<td>Signalling cascade that mediates the cell stress response</td>
<td>Expression is induced by butyrate</td>
</tr>
<tr>
<td>Bcl-2</td>
<td>B-cell CLL/lymphoma 2 protein family</td>
<td>Regulates apoptosis and cell survival. Consists of Bcl2 (anti-apoptosis), Bax, Bak and Bad (pro-apoptotic)</td>
<td>Involved in butyrate-induced apoptosis</td>
</tr>
<tr>
<td>HSP27</td>
<td>Heat shock protein 27</td>
<td>Cell stress response, apoptosis</td>
<td>Expression is induced by butyrate</td>
</tr>
<tr>
<td>TNFR</td>
<td>Tumour necrosis factor receptor family</td>
<td>Activation by TNF mediates the apoptotic response via the extrinsic pathway</td>
<td>Butyrate sensitises the cell to the apoptotic response occurring via TNFR activation</td>
</tr>
<tr>
<td>CYCS</td>
<td>Cytochrome c</td>
<td>Apoptosis</td>
<td>Butyrate induces cytochrome c release into the cytoplasm during apoptosis</td>
</tr>
<tr>
<td>TP53</td>
<td>Tumour protein p53</td>
<td>Tumour suppressor and cell cycle regulator</td>
<td>Activation by butyrate is one known mechanism involved in butyrate-induced apoptosis</td>
</tr>
<tr>
<td>MYC</td>
<td>c-myc</td>
<td>Transcription factor involved in cell cycle progression and apoptosis</td>
<td>Butyrate reduces expression</td>
</tr>
<tr>
<td>Inflammation and the immune response</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NF-$\kappa$B</td>
<td>Nuclear factor kappa beta family</td>
<td>Transcription factor involved in many cellular processes including inflammation, immune response and apoptosis</td>
<td>Activity of NF-$\kappa$B is influenced by butyrate to mediate expression of cytokines and chemokines involved in inflammation, e.g. interleukins, MCP1, GM-CSF, VEGF</td>
</tr>
<tr>
<td>COX2 (PGH2)</td>
<td>Cyclo-oxygenase-2 (prostaglandin G/H synthase 2)</td>
<td>Involved in inflammation by mediating prostaglandin synthesis</td>
<td>Reduced expression by butyrate in vitro, anti-inflammatory effect</td>
</tr>
<tr>
<td>TNF</td>
<td>Tumour necrosis factor family of proteins</td>
<td>Family of pro-inflammatory cytokines, binding to TNF activates extrinsic apoptotic pathway</td>
<td>Butyrate sensitises cells to TNFR activation to promote apoptosis</td>
</tr>
<tr>
<td>IL8</td>
<td>Interleukin 8</td>
<td>Inflammatory response</td>
<td>Butyrate reduces IL8 expression, anti-inflammatory effect</td>
</tr>
<tr>
<td>NOS1</td>
<td>Nitric oxide synthase 1, inducible</td>
<td>Catalyses formation of NO, a free radical involved with many biological processes including inflammation</td>
<td>Butyrate reduces NOS expression, anti-inflammatory effect</td>
</tr>
<tr>
<td>TXN</td>
<td>Thioredoxin</td>
<td>Modifies cysteine residue of target proteins via nitrosylation, removes intracellular NO and may play a role in the inflammatory and apoptotic response</td>
<td>Increased expression by butyrate alleviates oxidative stress response</td>
</tr>
<tr>
<td>PRDX</td>
<td>Peroxiredoxin family of proteins</td>
<td>Antioxidant enzymes</td>
<td>Increased expression by butyrate alleviates anti-inflammatory effect</td>
</tr>
<tr>
<td>GST</td>
<td>Glutathione S-transferase protein family</td>
<td>Cellular detoxification, metabolises toxins via conjugation to glutathione</td>
<td>Increased expression by butyrate, anti-inflammatory effect</td>
</tr>
<tr>
<td>Cancer cell metabolism</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIF-1</td>
<td>Hypoxia inducible factor</td>
<td>Transcription factor involved in energy metabolism, angiogenesis, apoptosis. Facilitates metabolic adaptation to hypoxic environments. Heterodimer consisting of $\alpha$ and $\beta$ subunits</td>
<td>Activated under hypoxic conditions, HIF activity is potentially indirectly regulated by butyrate</td>
</tr>
<tr>
<td>GLUT1</td>
<td>Glucose transporter type 1</td>
<td>Ubiquitously expressed, transports glucose into the cell. Elevated expression in cancer, including CRC</td>
<td>Not known if butyrate regulates GLUT1 expression directly</td>
</tr>
</tbody>
</table>
micro-RNA are non-protein coding RNA species that regulate translation of their respective mRNA targets. Over 1000 human miRNA have been identified (www.miBase.org accessed June 2011). Despite the intensity of effort, only a small number of miRNA, notably miR-31 and those of the miR-194/-215 and miR-143/-145 clusters, have consistently been associated with colorectal tumorigenesis (58).

In vitro studies have demonstrated that butyrate regulates the expression of miRNA in HCT116 cells and in human CRC stem cells characterised by CD133 cell surface expression when compared to respective control cells, including those mentioned previously(56,57). Establishing the role of miRNA in the regulation of gene transcription is still in its infancy and the true potential that butyrate may have on miRNA expression, or regulation of its function, remains to be elucidated.

Inflammation and the immune response

SCFA have anti-inflammatory effects in the large bowel. In patients with usual ulcerative colitis, the expression of inflammatory cytokines is suppressed in mucosal biopsies from the rectum and cecum (69). However, data derived from in vivo experiments where colorectal tumour tissue was exposed to butyrate have been inconclusive, possibly due to the size of the patient cohorts tested, tumour tissue heterogeneity and potential confounding by clinical parameters(68). This is a critical factor in validating the relevance of data derived from model systems to human CRC and it is highly desirable to invest in such an effort.

NF-κB is one of the primary contributors to the development of inflammation-associated carcinogenesis, including CRC arising from chronic inflammatory conditions such as ulcerative colitis(69). Although butyrate regulates the activity of NF-κB, the signalling mechanisms involved in this process are not known. Constitutive activation of NF-κB has been reported in approximately 40% of colorectal tumour tissues(70) and NF-κB activation in tumour cells promotes survival both by potentiating the inflammatory response through the activation of signalling pathways regulated by pro-inflammatory cytokines and by regulating the expression of anti-apoptotic genes(71,72).

Role of the SLC5A8 transporter in the inflammatory response and colorectal cancer

The Na-linked solute transporter SLC5A8 (solute carrier family 5, member 8) is silenced epigenetically in a number of different cancers(73). This transporter is expressed in the colon, kidney and thyroid and is represented in Table 1. Continued.

<table>
<thead>
<tr>
<th>Gene ID</th>
<th>Gene/protein name</th>
<th>Biological role</th>
<th>Effect of butyrate</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCT1 (SLC16A1)</td>
<td>Monocarboxylate transporter 1</td>
<td>Transports monocarboxylates, including SCFA into the cell</td>
<td>Primary butyrate transporter in the colon. Expression is decreased in CRC Epigenetically silenced in CRC</td>
</tr>
<tr>
<td>SMCT1 (SLC5A8)</td>
<td>Sodium-coupled monocarboxylate transporter 1</td>
<td>Transports monocarboxylates, including SCFA into the cell</td>
<td>Expression is reduced in CRC andactivation by butyrate and other SCFA potentially mediates the apoptotic response</td>
</tr>
<tr>
<td>GPR109A</td>
<td>G-protein coupled receptor 109A</td>
<td>Receptor expressed on plasma membrane of neutrophils and colonocytes</td>
<td>Expression is reduced in CRC and activation by butyrate and other SCFA potentially mediates the inflammatory response and induces apoptosis of CRC cells</td>
</tr>
<tr>
<td>GPR43</td>
<td>G-protein coupled receptor 43</td>
<td>Receptor expressed on plasma membrane of immune cells and possibly colonocytes</td>
<td>Expression is reduced in CRC and activation by butyrate and other SCFA potentially mediates the inflammatory response and induces apoptosis of CRC cells</td>
</tr>
</tbody>
</table>

JNK, c-Jun N-terminal kinase; ERK, extracellular signal-regulated kinase; MCP1, monocyte chemoattractant protein 1; GM-CSF, granulocyte-macrophage colony stimulating factor; VEGF, vascular endothelial growth factor; CRC, colorectal cancer.
recognises (and transports) monocarboxylic acids, including butyrate. Methylation of the SLC5A8 gene and its subsequent loss of expression have been detected in 59% of CRC adenoma and tumour tissues(73). Silencing of SLC5A8 in CRC has been associated with mutant and inactive adenomatous polyposis coli (APC) protein and aberrant Wnt signalling(74). In vitro studies have shown that butyrate transport by SLC5A8 inhibits HDAC activity and the growth of tumour cells(75,76). Thangaraju et al.(74) also reported that loss of SLC5A8 expression on CRC cell lines was inversely linked with apoptosis, and that apoptosis occurred as a result of inhibition of HDAC activity and activation of the caspase cascade by butyrate.

Involvement of SCFA receptors in the inflammatory response and colorectal cancer. SCFA augment the immune and inflammatory response by influencing immune cell functions such as chemotaxis, phagocytosis, reactive oxygen species production and cytokine/chemokine release. Butyrate reduces reactive oxygen species production and cytokine release in activated neutrophils (at approximately 1–6 mmol/1) and plays a role in immune cell migration in vitro(77,78). Recently, production of acetate by bifidobacteria was found to improve the immune defence function of intestinal epithelial cells in vitro(79). These effects have been attributed, in part, to the activation of G-protein coupled receptors (GPR), in particular GPR109A and GPR43. The GPR40 family comprises receptors for SCFA and medium-chain fatty acids, with GPR41 and GPR43 having the highest affinity for SCFA (<5 carbons)(80–82). Although these receptors display millimolar affinity for the SCFA, these concentrations are readily achievable in the colon. The role of GPR43 in inflammatory conditions has been studied widely using isolated immune cells and in mouse models of intestinal inflammation(81,83–85). In mouse models of both acute and chronic colitis induced by dextran sulphate sodium, absence of GPR43 expression resulted in greater colonic inflammation and compromised mucosal integrity when compared to wild-type littermates expressing the receptor(84). Consumption of acetate in the drinking water resulted in improved inflammatory indices in wild-type mice but not in GPR43 knockout mice, indicating that activation of this receptor by SCFA plays a role in modulating the inflammatory response. Conversely, Sina et al.(85) reported that loss of GPR43 expression reduced colonic inflammation in the chronic dextran sulphate sodium mouse model of colitis. These apparently contradictory results may be attributed to differences in the dose and duration of dextran sulphate sodium administration between these two studies. Nevertheless, both studies report that stimulation of GPR43 by SCFA (acetate(84) and propionate and butyrate(85)) is essential for immune cell recruitment and that this chemotactic response is mediated by the MAPK pathway.

GPR43 has been implicated in CRC prevention where it may have a tumour-suppressive role(86). Loss of GPR43 expression occurs in colorectal adenocarcinoma tissue when compared to normal mucosa and reduced expression has been noted in colorectal hyperplasia and benign colorectal disease including polyps(86). In a panel of nine CRC cell lines, Tang et al.(86) determined that GPR43 was expressed in the HT29 CRC cell line only. They established also that re-expression of this receptor in CRC cells and activation by either butyrate (50% inhibitory concentration (IC50) 0·8 mmol/l) or propionate (IC50 2 mmol/l) inhibited proliferation and induced apoptosis and cell cycle arrest, providing further support for the role of GPR43 in maintaining normal cellular function. This effect of propionate is important, as it has been reported to induce some effects which are similar to butyrate, albeit at much higher concentrations. GPR43 expression has been studied in the MCF7 breast cancer cell line where its activation by each of the SCFA (at 10 mmol/l) induced a cell stress response mediated specifically by p38 MAPK signalling(47). These data indicate that GPR43 plays a pivotal role in activating the signalling pathways associated with the reported cellular and anti-tumorigenic effects of butyrate (and other SCFA). Despite this, GPR43-mediated cell signalling events in both the normal colon, colonic inflammatory conditions and in the development of CRC need to be determined.

GPR109A was initially identified as the receptor for nicotinic acid(497–499) and belongs to a receptor subfamily that includes GPR81 and GPR109B(90). Although GPR109A and GPR109B are similar structurally and have a similar expression pattern, they differ in their ligand specificity(90,91). GPR109A is activated by nicotinic acid, 3-hydroxybutyrate and butyrate, whereas GPR109B displays much lower affinity for butyrate. GPR109A binds and activates the GPR109A receptor (50% effective concentration (EC50) 1·6 mmol/l), but has no effect on GPR109B and neither receptor displays affinity for acetate or propionate(91). GPR109A is expressed in the human colon and the expression of this receptor is dysregulated in CRC(92). A similar expression pattern was also determined in a mouse model of CRC and in a panel of human CRC cell lines. The authors determined also that silencing of GPR109A in CRC occurs as a result of DNA methylation. Subsequent re-expression of GPR109A in CRC cell lines and its activation by 1 mmol/l butyrate abolished NF-kB activation and induced apoptosis. Apoptosis occurred independently of HDAC inhibition, lending further support to the existence of alternate mechanisms involved in butyrate-induced apoptosis. Although GPR109A is also expressed on immune and inflammatory cells, its role in these cells has yet to be determined.

Cancer cell metabolism

Tumour cells display an altered cellular metabolism that can be viewed as an adaptive response to an hypoxic microenvironment or as a result of mutations in oncogenes and tumour-suppressor genes leading to higher glycolytic activity and enhanced energy production – a phenomenon known as the ‘Warburg effect’(93). Although this characteristic of cancer cells has been studied widely, the mechanisms linking this switch in cell metabolism from a normal phenotype to cancer cell survival are uncertain. Transcription factors such as hypoxia inducible factor (HIF), tumour protein p53, octamer-binding protein 1 (OCT1), NF-KB and avian myelocytomatosis viral oncogene homolog (MYC) have been linked to dysregulated expression of nutrient transporters, glycolytic enzymes, and proteins involved in mitochondrial function(94).
and it is possible that butyrate may target these transcription factors to alter cell metabolism. In vitro studies and those involving isolated human colonocytes have indicated that butyrate modulates the levels and activity of transcription factors. In the case of c-myc, 5 mmol/l butyrate inhibits its transcription and protein expression in malignant cells, possibly via its ability to inhibit HDAC activity (95,96). In vitro studies also demonstrate that, while butyrate increases transcription of the HIF-1α gene, it represses the transcriptional regulatory activity of HIF-1α protein by inhibiting its translocation to the nucleus in Caco2 cells (97,98). These studies demonstrate further that inhibition of VEGF expression and angiogenesis occurs with butyrate incubation, but the effects on cellular metabolism were not investigated. Regulation of HIF-1α translocation by butyrate presents a potential mechanism contributing to its effects on angiogenesis.

Regulation of cancer cell metabolism by butyrate.

Recent studies have shown that CRC cells, which are highly dependent on glycolysis, can acquire a unique ability to utilise both butyrate and glucose as their energy source and that this metabolic switch can be induced by the former (96). This capacity for both butyrate and glucose metabolism by colorectal tumour cells is supported by an elevated expression of solute transporters with high affinity for either substrate. In particular, monocarboxylate transporter 1 (MCT1, SLC16A1 (solute carrier family 16, member 1)) and GLUT type 1 (GLUT1, SLC2A1 (solute carrier family 2, member 1)) are elevated in CRC tissue when compared to adjacent normal mucosa (99,100). MCT1 is expressed widely in many different cell types and has been characterised as the primary butyrate transporter in the colon. It is expressed in healthy colon tissue and in many different cultured CRC cell lines (101,102). Reports on the expression of MCT1 in CRC tissue have been conflicting with reported increases (99,100) or decreases (103) in expression. In addition to facilitating butyrate entry into the cell, MCT1 functions to remove lactate, a potentially cytotoxic metabolic by-product of glycolysis, indicating that it plays a dual role to enhance the survival of CRC cells (99). Butyrate also increases the expression of MCT1 on CRC cells in a dose-dependent manner and this is partially attributed to NF-κB activity (104).

GLUT1 is expressed widely and its expression is elevated in cells from many different types of cancer. Its level of expression in tumours, including CRC, has been correlated with poor clinical outcomes (105). The mechanisms involved in the regulation of GLUT1 expression in cancer cells are not completely understood. Induction of its expression has been linked with a hypoxic microenvironment and regulation by HIF-1. However, there are alternative mechanisms (106). Using a panel of CRC cell lines, Yun et al. (107) recently showed that increased GLUT1 expression is independent of HIF-1 activity and may instead be a downstream consequence of dysregulated signalling pathways caused by mutations in the KRAS or BRAF (v-raf murine sarcoma viral oncogene homolog B1) genes. It is not known if butyrate is able to regulate the expression of GLUT1 in CRC cells.

Although these findings are contradictory, they can be reconciled if this altered metabolic profile is due to the presence of a butyrate-resistant sub-population of CRC cells. These cells would not succumb to apoptosis with butyrate exposure, but could proliferate to establish tumours. In the Caco2 CRC cell line, butyrate inhibits the pyruvate dehydrogenase complex, reducing the capacity for glycolysis and inducing a switch to a butyrate-oxidising phenotype providing a potential explanation for the development of a butyrate-resistant cell population (108). This is an established feature of the regulation of pyruvate dehydrogenase in a number of tissues. Glutamine metabolism was increased to favour the production of precursors for fatty acid synthesis, a process essential for cell proliferation. The group further demonstrated that this metabolic switch occurred as a result of HDAC inhibition by butyrate.

Recently, a link was established between HIF-1α and APC, further supporting the role of HIF-1α in the early stages of carcinogenesis (109). In this study, HIF-1α was found to bind directly to the promoter region of APC, inhibiting its expression and (potentially) enhancing tumour cell survival (109). This study also showed that depletion of wild-type APC protein, but not a mutant one, resulted in elevated HIF-1α activity. Mutations in APC are common to CRC, and thus up-regulation of HIF-1α in these cells may provide a further competitive advantage to tumour cells by altering their metabolism to promote adaptation to an hypoxic environment. Limitations in O2 supply could be an important factor in CRC development and also help to explain some of the unanswered questions in the aetiology of the disease. Cigarette smoking is an established risk factor for CRC and heavy use leads to the significant accumulation of erythrocyte carbonmonoxyhaemoglobin (110). Blood carbonmonoxyhaemoglobin leads to substantial changes in metabolic processes (e.g. ethanol metabolism (111) and lipoprotein metabolism (112)) through decreased tissue O2 consumption. In contrast, greater SCFA production (through fermentation) leads to greater visceral perfusion and, hence, increased O2 supply although infusion studies suggest that the effect of butyrate is rather less than the other SCFA (12).

Butyrate and butyrate analogues as chemotherapeutic agents.

HDAC inhibitors are being investigated seriously as potential chemotherapeutic agents. Suberoylanilide hydroxamic acid was recently approved for the treatment of cutaneous T-cell lymphoma (113). Experiments with various cancer cell lines have been conducted to determine if combined treatment with DNA methyltransferase inhibitors (e.g. 5-aza-2′-deoxycytidine) and prototype HDAC inhibitors (e.g. trichostatin A, butyrate) could restore the function of key tumour-suppressor genes (114). Studies such as these are aimed primarily at determining the potential efficacy of combined treatments for cancer therapy. Butyrate itself is disqualified as a candidate chemotherapeutic agent on several counts. These include its ready uptake and metabolism by many cell types in the body, leading to rapid clearance and short half-life in the circulation. To overcome these limitations, many studies have explored the potential of butyrate derivatives, with 4-phenylbutyrate and tributyryl being the most promising (115–118). In vitro studies comparing
Butyrate in colorectal cancer prevention

**Fig. 2.** Summary of the anti-tumorigenic effects of butyrate. HDAC, histone deacetylase; miRNA, micro-RNA; GPR43, G-protein coupled receptor 43; GPR109A, G-protein coupled receptor 109A; ROS, reactive oxygen species; COX2, cyclo-oxygenase-2; HIF-1α, hypoxia inducible factor.

The structural analogues of butyrate have shown that the apoptotic properties of butyrate are dependent on the lack of substitution at the 2- and 3-positions of the carboxylate backbone\(^{119,120}\). Furthermore, these studies identified 4-benzoylbutyrate and 4-phenylbutyrate to be the most potent of the thirty-two analogues compared, indicating that a three-atom spacer between any bulky moiety and carboxyl group may also be essential for the anti-tumorigenic properties of any butyrate-based pharmaceutical. Although these studies did not identify analogues that were more potent than butyrate in vitro, they provide a starting point for the development of novel therapeutic agents.

**Conclusion and future perspectives**

CRC is a disease where there is clear potential for lowering the risk through dietary and lifestyle changes, with 30–60% of tumours being preventable. The evidence available suggests that the consumption of diets high in fibre, in particular RS, and low in fats and proteins is protective against CRC development. The role of fibre fermentation is an area of growing significance in disease aetiology, with increasing attention being given to SCFA\(^{121}\). It appears that SCFA mediate many of the effects previously ascribed to fibre alone. Butyrate is central to the proposed link between diet and protection against CRC. There appears to be a clear pathway that integrates, at a population level, the beneficial effects of a high-fibre diet (especially fermentable fibre), the formation of SCFA by colonic microbiota and demonstration of a role for the SCFA in maintaining physiological function in the colon including cell growth and regulation. Key to this hypothesis is the ability of butyrate to influence cellular processes to support a normal cell population and induce apoptosis and inhibit tumorigenesis (Fig. 2). While in vitro experiments indicate that HDAC inhibition is the primary mechanism for butyrate’s anti-tumorigenic effects, the evidence for additional cellular pathways contributing to butyrate’s pro-apoptotic and anti-proliferative activities in tumour cells is mounting. The current body of knowledge offers promise for containing CRC, but it is a clear priority to delineate these mechanisms in experimental systems and move on to human population and intervention studies to determine their true potential for risk reduction. Nutritional trials in free-living subjects have shown that it is possible to raise faecal SCFA (including butyrate) to levels found in low-risk populations such as native Africans consuming traditional foods\(^{122,123}\). Although these studies demonstrate that such interventions are feasible, it appears that some individuals do not show the expected rise in SCFA on increasing RS consumption\(^{123}\). This may reflect differences in the capacity of their large-bowel microbiome to ferment starch\(^{124}\). Clearly, it is imperative to show that any increase in colonic butyrate supply can be effective and sustained.

**Acknowledgements**

The authors would like to thank Dr Leanne Purins and Dr Julie Clarke for helpful discussions. The present work was supported by the CSIRO Preventative Health and Food Futures National Research Flagships. The authors declare no conflicts of interest. K. Y. C. F., D. L. T. and R. H. wrote the manuscript. K. Y. C. F., L. C., T. L., R. H. and D. L. T. contributed to the ideas and participated in the editing. All authors read and approved the final manuscript.

**References**


